CliffBio
small molecule

DOXYCYCLINE HYCLATE

DOXYCYCLINE HYCLATE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOXYCYCLINE HYCLATE
Active ingredientDOXYCYCLINE HYCLATE
StrengthEQ 50MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1984
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DOXYCYCLINE HYCLATE patent cliff — loss of exclusivity — | CliffBio